Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company
Wells Fargo & Company upgraded shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) from an underweight rating to an equal weight rating in a report published on Friday morning, MarketBeat Ratings reports. Wells Fargo & Company currently has $8.00 price objective on the stock. Other equities analysts have also recently issued research reports about the […]
Wells Fargo & Company upgraded shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) from an underweight rating to an equal weight rating in a report published on Friday morning, MarketBeat Ratings reports. Wells Fargo & Company currently has $8.00 price objective on the stock. Other equities analysts have also recently issued research reports about the […]
